268 related articles for article (PubMed ID: 25308513)
1. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.
Xie C; Edwards H; Caldwell JT; Wang G; Taub JW; Ge Y
Mol Oncol; 2015 Feb; 9(2):409-21. PubMed ID: 25308513
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.
Xie C; Edwards H; Xu X; Zhou H; Buck SA; Stout ML; Yu Q; Rubnitz JE; Matherly LH; Taub JW; Ge Y
Clin Cancer Res; 2010 Nov; 16(22):5499-510. PubMed ID: 20889917
[TBL] [Abstract][Full Text] [Related]
3. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
[TBL] [Abstract][Full Text] [Related]
7. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
O' Reilly E; Dhami SPS; Baev DV; Ortutay C; Halpin-McCormick A; Morrell R; Santocanale C; Samali A; Quinn J; O'Dwyer ME; Szegezdi E
Sci Rep; 2018 Oct; 8(1):15752. PubMed ID: 30361682
[TBL] [Abstract][Full Text] [Related]
8. A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
Jin J; Mao S; Li F; Li X; Huang X; Yu M; Guo W; Jin J
Med Oncol; 2019 Aug; 36(9):77. PubMed ID: 31372848
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Xie C; Edwards H; Lograsso SB; Buck SA; Matherly LH; Taub JW; Ge Y
Pediatr Blood Cancer; 2012 Dec; 59(7):1245-51. PubMed ID: 22488775
[TBL] [Abstract][Full Text] [Related]
10. The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells.
Opydo-Chanek M; Cichoń I; Rak A; Kołaczkowska E; Mazur L
Invest New Drugs; 2020 Dec; 38(6):1664-1676. PubMed ID: 32367199
[TBL] [Abstract][Full Text] [Related]
11. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
Xie C; Drenberg C; Edwards H; Caldwell JT; Chen W; Inaba H; Xu X; Buck SA; Taub JW; Baker SD; Ge Y
PLoS One; 2013; 8(11):e79106. PubMed ID: 24244429
[TBL] [Abstract][Full Text] [Related]
12. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
13. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
[TBL] [Abstract][Full Text] [Related]
15. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
Zhang H; Kang J; Liu L; Chen L; Ren S; Tao Y
Aging (Albany NY); 2020 Oct; 12(20):20111-20126. PubMed ID: 33077697
[TBL] [Abstract][Full Text] [Related]
17. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
[TBL] [Abstract][Full Text] [Related]
18. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
19. Coculture in vitro with endothelial cells induces cytarabine resistance of acute myeloid leukemia cells in a VEGF-A/VEGFR-2 signaling-independent manner.
Okamoto S; Miyano K; Kitakaze K; Kato H; Yamauchi A; Kajikawa M; Itsumi M; Kawai C; Kuribayashi F
Biochem Biophys Res Commun; 2022 Jan; 587():78-84. PubMed ID: 34872003
[TBL] [Abstract][Full Text] [Related]
20. CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1.
Yakymiv Y; Augeri S; Bracci C; Marchisio S; Aydin S; D'Ardia S; Massaia M; Ferrero E; Ortolan E; Funaro A
Sci Rep; 2021 Oct; 11(1):21230. PubMed ID: 34707185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
